EA201301341A1 - PHARMACEUTICAL COMPOSITION, POSSESSING PANCREOTOPROTECTIVE ACTION, ITS APPLICATION FOR PREVENTION OR TREATMENT OF PANCREATITIS AND METHOD OF PREVENTION AND TREATMENT OF PANCREATITIS - Google Patents
PHARMACEUTICAL COMPOSITION, POSSESSING PANCREOTOPROTECTIVE ACTION, ITS APPLICATION FOR PREVENTION OR TREATMENT OF PANCREATITIS AND METHOD OF PREVENTION AND TREATMENT OF PANCREATITISInfo
- Publication number
- EA201301341A1 EA201301341A1 EA201301341A EA201301341A EA201301341A1 EA 201301341 A1 EA201301341 A1 EA 201301341A1 EA 201301341 A EA201301341 A EA 201301341A EA 201301341 A EA201301341 A EA 201301341A EA 201301341 A1 EA201301341 A1 EA 201301341A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pancreatitis
- prevention
- treatment
- pharmaceutical composition
- glu
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к медицине и касается фармацевтической композиции, содержащей пептиды Asp-Glu-Gly, Lys-Asp-Glu, Ala-Asp-Glu-Leu. Композиция обладает выраженным панкреопротекторным действием, что позволяет использовать фармацевтическую композицию, содержащую пептиды Asp-Glu-Gly, Lys-Asp-Glu, Ala-Asp-Glu-Leu для профилактики или лечения панкреатита.The invention relates to medicine and relates to a pharmaceutical composition comprising peptides Asp-Glu-Gly, Lys-Asp-Glu, Ala-Asp-Glu-Leu. The composition has a pronounced pancreatic action that allows the use of a pharmaceutical composition containing peptides Asp-Glu-Gly, Lys-Asp-Glu, Ala-Asp-Glu-Leu for the prevention or treatment of pancreatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201301341A EA023136B1 (en) | 2013-12-26 | 2013-12-26 | Pharmaceutical composition possessing pancreoprotective activity, use thereof for prevention and/or treatment of pancreatitis and method for prevention and treatment of pancreatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201301341A EA023136B1 (en) | 2013-12-26 | 2013-12-26 | Pharmaceutical composition possessing pancreoprotective activity, use thereof for prevention and/or treatment of pancreatitis and method for prevention and treatment of pancreatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201301341A1 true EA201301341A1 (en) | 2015-06-30 |
| EA023136B1 EA023136B1 (en) | 2016-04-29 |
Family
ID=53488010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201301341A EA023136B1 (en) | 2013-12-26 | 2013-12-26 | Pharmaceutical composition possessing pancreoprotective activity, use thereof for prevention and/or treatment of pancreatitis and method for prevention and treatment of pancreatitis |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA023136B1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2341282C2 (en) * | 2007-01-24 | 2008-12-20 | Общество с ограниченной ответственностью "БИОН" | Pharmaceutical composition of pancreatropic activity and method of pharmaceutical composition production |
| RU2482128C1 (en) * | 2011-12-28 | 2013-05-20 | Замертон Холдингс Лимитед | Peptides possessing cytoprotective activity |
-
2013
- 2013-12-26 EA EA201301341A patent/EA023136B1/en active IP Right Revival
Also Published As
| Publication number | Publication date |
|---|---|
| EA023136B1 (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20160582A (en) | COMPOSITION TO TREAT DIABETES, CONTAINING A PROLONGED ACTION INSULIN ANALOG AND A PROLONGED ACTION INSULINOTROPIC PEPTIDE CONJUGATE | |
| EA033325B1 (en) | Bromodomain inhibitors | |
| MX378273B (en) | ACTIVE COMPOUNDS TOWARDS BROMODOMAINS. | |
| EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| EA201690159A1 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| EA201790575A1 (en) | TRIAZOLOPIRASINONS AS PDE1 INHIBITORS | |
| MX2016011810A (en) | Pharmaceutical compositions of therapeutically active compounds. | |
| EA201691481A1 (en) | C5a inhibitors for the treatment of viral pneumonia | |
| EA201792157A1 (en) | IMIDAZOPIRASINONS AS PDE1 INHIBITORS | |
| EA201690039A1 (en) | RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION | |
| EA201692007A1 (en) | IZOINDOLINON COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA, AND RELATED DISORDERS | |
| MX376200B (en) | NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA. | |
| EA201692008A1 (en) | SUBSTITUTED CONDENSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS | |
| EA201791454A1 (en) | DRUG FORMS FOR TRANSDERMAL ADMINISTRATION | |
| MX2019001634A (en) | AMIDAS COMPOUNDS, PHARMACEUTICAL COMPOSITIONS OF THESE AND METHODS TO USE THEM. | |
| EA201690783A1 (en) | SUBSTANCES, PHARMACEUTICAL COMPOSITION AND METHODS OF APPLICATION IN THE TREATMENT OF INFLAMMATORY DISEASES | |
| EA201792262A1 (en) | PIROGLUTAMAT VORTIOKSETINA | |
| EA201691108A1 (en) | Quinazoline-THF-Amines as PDE1 Inhibitors | |
| EA201691773A1 (en) | HALOGENATED HINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | |
| EA201691335A1 (en) | HEXAHYDROFUROPYRROLES AS INHIBITORS PDE1 | |
| PH12018550008A1 (en) | Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse | |
| CR20160353A (en) | CHOLESTERILE ESTER TRANSFER PROTEIN INHIBITOR (CETP) AND PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| PL3203998T3 (en) | SUBSTITUTE AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | |
| MA40642A (en) | Novel peptide derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ RU |
|
| NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): AM AZ BY KZ RU |
|
| PC4A | Registration of transfer of a eurasian patent by assignment |